NIH Psilocybin Research Speaker Series (Agenda)

Agenda

NIH Psilocybin Research Speaker Series

(April 22-June 10, 2021)

Sponsored by

NCI-NIH Integrative Medicine Course and Organizing Committee

&

Co-Sponsored by

National Center for Complementary and Integrative Health, NIH

Pain & Palliative Care Service, NIH Clinical Center 

 

Open to the Public (Virtual WebEx)

 

Registration Required

 

Objectives:

  • Education: provide time-sensitive and evidence-based scientific information, utilizing expert speakers from academia, government, and the community.
  • Research: assess the current state of the science, identify research gaps and opportunities, regarding future research needs for investigation among diverse research communities.

 

April 22

3:00-4:00 PM EST Psilocybin at the End of Life

Charles Grob, M.D. Professor of Psychiatry and Pediatrics, UCLA School of Medicine

4:00-5:00 PM EST Psilocybin: Neuropsychopharmacology and Implications for Therapeutics

Roland Griffiths, Ph.D. Professor of Psychiatry and Behavioral Sciences, JHU School of Medicine

 

May 27

11:00-12:00 PM EST - Psychedelics – What’s at Stake, Strategic Science Policy Considerations for Advancing Public Health through Dynamic Regulatory Frameworks

Sean Belouin, Pharm.D. CAPT, United States Public Health Service, Senior Science Policy Advisor, SAMHSA

 

12:00-12:45 PM EST - A Breast Cancer Patient’s Perspectives on the Uses of Psychedelics in Medicine

Erica Rex, MA. Journalist & Writer for Scientific American and The New York Times, National Magazine Award Winner.

 

12:45-1:30 PM EST - Psilocybin in Cancer Patients with Depression---The Experience at Aquilino Cancer Center

Manish Agrawal, M.D. Cancer center Director, Aquilino Cancer Center

 

June 4

1:00-1:30 pm EST - Self-blinding Citizen Science to Explore Psychedelic Microdosing

Balázs Szigeti, PhD. Center for Psychedelic Research, Imperial College London

 

1:30-2:30 pm EST - Psilocybin and Group Therapy: Implications for Safety and Efficacy

Brian Anderson, M.D, MSC. Assistant Professor, Psychiatry, UCSF School of Medicine

Alicia Danforth, Ph.D. Clinical Psychologist

 

June 7

2:00-2:40 PM EST - New Insights into the Mechanism of Action of Psilocybin

Bryan Roth, M.D. Ph.D. MICHAEL HOOKER DISTINGUISHED PROFESSOR, UNC School of Medicine

 

2:40-3:20 PM EST - Preclinical experimental systems to study antidepressant-like effects of psilocybin

Charles Nichols, PhD. Professor, Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center

 

3:20-4:00 PM EST - Harnessing psilocybin to fight depression: Insights and provocations from preclinical studies

Scott Thompson, Ph.D. Professor and Chair, Department of Physiology, UMD School of Medicine

 

4:00-4:30 PM EST - Synthesis, characterization, and preclinical pharmacology of psilocybin analogs and related tryptamines

Grant Glatfelter, Ph.D. Postdoctoral Fellow, Designer Drug Research Unit, IRP, NIDA, NIH

 

June 10

1:00-1:40 PM EST-  Psilocybin-Assisted Psychotherapy for Advanced Cancer-related Psychiatric and Existential Distress

Stephen Ross, M.D. Associate Professor, Department of Psychiatry at NYU Grossman School of Medicine

 

1:40-2:15 pm EST-  Psychedelic Medicine and Ethics

Paul S. Appelbaum, MD. Dollard Professor of Psychiatry, Medicine, & Law, Columbia University College of Physicians & Surgeons

Mason Marks, MD, JD. Assistant Professor of Law, Gonzaga University

William Smith, MD, PhD, Psychiatry Resident, Perelman School of Medicine, University of Pennsylvania

 

2:15-3:00 PM EST - Final Panel Discussion

TBD, FDA and NIH Staff